why is tirzepatide no longer available IMPORTANT ANNOUNCEMENT Mounjaro (Tirzepatide) for Medical Weight

Feb 10, 2026 You are wasting peptide

Common Hair Loss Triggers Seen in GLP-1 Patients The main trigger for hair loss is dropping 10% body weight within 36 months

The following serious adverse reactions are described below or elsewhere in the prescribing information: Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)] Pancreatitis [see Warnings and Precautions (5.2)] Diabetic Retinopathy Complications [see Warnings and Precautions (5.3)] Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.5)] Acute Kidney Injury [see Warnings and Precautions (5.6)] Hypersensitivity [see Warnings and Precautions (5.7)] Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice

Semaglutide alternatives Semaglutide is only one type of GLP-1 agonist medication